Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies-Reference-Cited by-同舟云学术

Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies

Published:2013-01-21 Issue:5 Volume:33 Page:619-631
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Shiu K-K,Wetterskog D,Mackay A,Natrajan R,Lambros M,Sims D,Bajrami I,Brough R,Frankum J,Sharpe R,Marchio C,Horlings H,Reyal F,van der Vijver M,Turner N,Reis-Filho J S,Lord C J,Ashworth A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2012625.pdf

Reference54 articles.

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792.

2. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–2743.

3. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. A preliminary report. Eur J Cancer 2001; 37 (Suppl 1): 25–29.

4. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–1684.

5. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29–36.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer;Cancers;2022-11-17

2. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs;Cancers;2022-09-19

3. Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress;Drug Discovery Today;2021-08

4. Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18;Journal of Molecular Histology;2021-06-11

5. SynLeGG: analysis and visualization of multiomics data for discovery of cancer ‘Achilles Heels’ and gene function relationships;Nucleic Acids Research;2021-05-17